AegirBio AB (52Q0) AI Stock Analysis

0 Followers

AegirBio AB

(Frankfurt:52Q0)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Strong Revenue ExpansionThe sharp TTM revenue increase indicates improving commercial traction and expanding business scale. If sustained, stronger sales can provide operating leverage, support broader market development, and create a foundation for reducing the gap between current revenue growth and eventual profitability.

Negative Factors

Severe and Persistent LossesVery large operating and net losses show that revenue growth is not yet translating into a sustainable earnings model. With costs rising faster than the business is scaling, the company faces a prolonged path to breakeven and may need significant operational improvement before profits become durable.

AegirBio AB (52Q0) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 5.61M
Dividend Yield: ―
Average Volume (3M): ―
Price to Earnings (P/E): -0.2
Beta (1Y): 7.94
Revenue Growth: ―
EPS Growth: ―
Country: Germany
Employees: 251
Sector: Technology
Sector Strength: 61
Industry: Software - Infrastructure

AegirBio AB Business Overview & Revenue Model

Company Description

Subgen AI AB develops artificial intelligence-based models and applications to control data for government and businesses. The company engages in the provision of information society services aimed at delivering financial and related knowledge tools...

AegirBio AB Peers Comparison

Overall Rating

UnderperformOutperform

Sector (61)

Financial Indicators

DE:52Q0 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SE:GENI	91Outperform	SEK 480.62M	14.28	―	4.75%	6.76%	1.88%
SE:CARA	73Outperform	SEK 1.73B	44.80	―	―	―	―
Sector *	61Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
SE:SLEEP	60Neutral	SEK 499.84M	41.14	17.62%	2.18%	-17.74%	-79.85%
SE:SEYE	51Neutral	SEK 1.80B	-13.34	―	―	35.21%	40.30%
SE:QCORE	38Underperform	SEK 13.73M	-0.32	―	―	-18.34%	59.68%

* Technology Sector Average

Performance Comparison

DE:52Q0 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:52Q0	AegirBio AB	0.01	-0.52	-98.11%
SE:SLEEP	Sleep Cycle AB	24.30	2.23	10.08%
SE:QCORE	Qlucore AB	0.32	-0.21	-39.62%
SE:GENI	Generic Sweden AB	36.85	-8.78	-19.25%
SE:CARA	Carasent AB	25.65	-2.15	-7.73%
SE:SEYE	Smart Eye AB	45.50	-41.55	-47.73%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

AegirBio AB AI Stock Analysis